Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
BI BIIB BIOGEN INC. FY ended Feb 04, 2026 | $218.50 | $32.26B | $29.36B | $9.89B | $2.60B | $1.29B | 24.86x | 3.26x | 10.24x |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 13.01x | 4/5 | $13.35B | $53.88 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 4.32x | 5/5 | $10.02B | $40.44 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 18.64x | 5/5 | $14.59B | $58.88 | Included in the active peer mix. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
BI BIIB BIOGEN INC. FY ended Feb 04, 2026 | $218.50 | $32.26B | $29.36B | $9.89B | $2.60B | $1.29B | 24.86x | 3.26x | 10.24x |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 13.01x | 4/5 | $13.35B | $53.88 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 4.32x | 5/5 | $10.02B | $40.44 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 18.64x | 5/5 | $14.59B | $58.88 | Included in the active peer mix. |
